Following the recent publication of the results of the COVA clinical trial (phase 2-3) in eClinicalMedicine (The Lancet), Biophytis organized a webcast to present the Group’s ambitions in the treatment of respiratory viral infections such as Covid-19 and influenza. https://vimeo.com/905775870
During the 25th annual H.C. Wainwright Global Investment Conference, Biophytis’ CEO Stanislas Veillet presented the company, its ambitions and the latest progress it made on its various projets. A replay will be available for 90 days at the following link: https://journey.ct.events/view/1037e68b-3f79-4b25-9a15-27affba4d7c4 Watch here
Biophytis : nouvelles positives en matière d’autorisations et de financement
Decoding #BIOTECH on Maddyness Read in French “Covid-19 : ces BioTech françaises engagées dans la course aux traitements” Read article in French on www.maddyness.com
Biophytis hosted a virtual key opinion leader (KOL) event on October 6th, 2021, on its lead projects, Sarconeos (BIO101) for the treatment of COVID-19 and Sarcopenia
Stanislas Veillet tells us in video on the active preparation of the marketing of Sarconeos for the first half of 2022